AG真人官方

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025.

"We are delighted to welcome Eric to the executive team,鈥� said Thomas Zindrick, President, CEO, and Chairman of the Board. 鈥淓ric brings a powerful blend of legal expertise, global business development savvy, and a strategic understanding of the biotechnology ecosystem. His proven ability to lead high-impact transactions, build trusted partnerships, and navigate complex regulatory environments will be invaluable in shaping our next phase of growth.鈥�

Mr. Groen is an accomplished executive who has over two decades of leadership in the life sciences industry, driving results, empowering teams, and shaping positive corporate culture. Recognized as a strategic yet hands-on executive, he is passionate about advancing innovation to improve patient outcomes and is eager to help Genelux realize the full potential of Olvi-Vec for patients, shareholders, and employees.

Most recently, Mr. Groen served as General Counsel of Rani Therapeutics, a clinical-stage, publicly traded biotech company. Previously, he spent 20 years in the legal department at Amgen with a proven track record in business development transactions such as Amgen鈥檚 $10 billion acquisition of Onyx Pharmaceuticals. Mr. Groen offers deep expertise across corporate law, mergers and acquisitions, licensing, compliance, and business development. He graduated from Harvard Law School with his J.D. and from the University of California, Santa Barbara with a B.A. in Political Science.

鈥淚鈥檓 honored to join Genelux at such a pivotal time,鈥� said Mr. Groen. 鈥淭his is a company with a compelling vision, exciting science, and a clear path to impact. I look forward to working alongside this talented team to help drive strategic growth, expand our collaborations and regional partnerships, and bring Olvi-Vec to patients who are urgently waiting for new options.鈥�

In connection with his appointment, Mr. Groen was granted an inducement award of a stock option to purchase 270,000 shares of common stock under Genelux鈥檚 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), at an exercise price of $2.83 per share. The inducement award will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to Mr. Groen鈥檚 continued service relationship with the company through the applicable vesting dates.

About Genelux Corporation
Genelux聽is a late-stage clinical biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Genelux鈥檚 most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of聽Genelux's聽discovery and development efforts revolves around its proprietary CHOICE鈩� platform from which the company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit聽聽and follow us on Twitter聽聽and on聽.

Forward-Looking Statements
This release contains 鈥渇orward-looking statements鈥� within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. 鈥淔orward-looking statements鈥� describe future expectations, plans, results, or strategies and are generally preceded by words such as 鈥渂elieves,鈥� 鈥渁nticipates,鈥� 鈥渆xpect,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥渓ook forward鈥� or 鈥渨ill鈥�. Forward-looking statements in this release include, but are not limited to, statements related to Mr. Groen鈥檚 expected contribution to Genelux, Olvi-Vec鈥檚 development plans and the realization of Olvi-Vec鈥檚 full potential. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified under the caption 鈥淩isk Factors鈥� in Genelux鈥檚 filings with the聽Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management鈥檚 assumptions and estimates as of such date.聽Genelux聽does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Investor and Media Contacts

Ankit Bhargava, MD
Allele Communications, LLC
[email protected]

Source: Genelux Corporation

A photo accompanying this announcement is available at聽